High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease 2019

The outbreak of coronavirus disease 2019 (COVID-19) has spread rapidly in China. Until now, no definite effective treatment has been identified. We reported on 3 patients with severe COVID-19 who received high-dose intravenous immunoglobulin (IVIg) with satisfactory recovery. Based on these observat...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Wei, Liu, Xiaosheng, Bai, Tao, Fan, Hongwei, Hong, Ke, Song, Hui, Han, Yang, Lin, Ling, Ruan, Lianguo, Li, Taisheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7111600/
https://www.ncbi.nlm.nih.gov/pubmed/32258207
http://dx.doi.org/10.1093/ofid/ofaa102
_version_ 1783513315628023808
author Cao, Wei
Liu, Xiaosheng
Bai, Tao
Fan, Hongwei
Hong, Ke
Song, Hui
Han, Yang
Lin, Ling
Ruan, Lianguo
Li, Taisheng
author_facet Cao, Wei
Liu, Xiaosheng
Bai, Tao
Fan, Hongwei
Hong, Ke
Song, Hui
Han, Yang
Lin, Ling
Ruan, Lianguo
Li, Taisheng
author_sort Cao, Wei
collection PubMed
description The outbreak of coronavirus disease 2019 (COVID-19) has spread rapidly in China. Until now, no definite effective treatment has been identified. We reported on 3 patients with severe COVID-19 who received high-dose intravenous immunoglobulin (IVIg) with satisfactory recovery. Based on these observations, randomized studies of high-dose IVIg should be considered in deteriorating patients infected with COVID-19.
format Online
Article
Text
id pubmed-7111600
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-71116002020-04-06 High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease 2019 Cao, Wei Liu, Xiaosheng Bai, Tao Fan, Hongwei Hong, Ke Song, Hui Han, Yang Lin, Ling Ruan, Lianguo Li, Taisheng Open Forum Infect Dis Brief Report The outbreak of coronavirus disease 2019 (COVID-19) has spread rapidly in China. Until now, no definite effective treatment has been identified. We reported on 3 patients with severe COVID-19 who received high-dose intravenous immunoglobulin (IVIg) with satisfactory recovery. Based on these observations, randomized studies of high-dose IVIg should be considered in deteriorating patients infected with COVID-19. Oxford University Press 2020-03-21 /pmc/articles/PMC7111600/ /pubmed/32258207 http://dx.doi.org/10.1093/ofid/ofaa102 Text en © The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Brief Report
Cao, Wei
Liu, Xiaosheng
Bai, Tao
Fan, Hongwei
Hong, Ke
Song, Hui
Han, Yang
Lin, Ling
Ruan, Lianguo
Li, Taisheng
High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease 2019
title High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease 2019
title_full High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease 2019
title_fullStr High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease 2019
title_full_unstemmed High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease 2019
title_short High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease 2019
title_sort high-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7111600/
https://www.ncbi.nlm.nih.gov/pubmed/32258207
http://dx.doi.org/10.1093/ofid/ofaa102
work_keys_str_mv AT caowei highdoseintravenousimmunoglobulinasatherapeuticoptionfordeterioratingpatientswithcoronavirusdisease2019
AT liuxiaosheng highdoseintravenousimmunoglobulinasatherapeuticoptionfordeterioratingpatientswithcoronavirusdisease2019
AT baitao highdoseintravenousimmunoglobulinasatherapeuticoptionfordeterioratingpatientswithcoronavirusdisease2019
AT fanhongwei highdoseintravenousimmunoglobulinasatherapeuticoptionfordeterioratingpatientswithcoronavirusdisease2019
AT hongke highdoseintravenousimmunoglobulinasatherapeuticoptionfordeterioratingpatientswithcoronavirusdisease2019
AT songhui highdoseintravenousimmunoglobulinasatherapeuticoptionfordeterioratingpatientswithcoronavirusdisease2019
AT hanyang highdoseintravenousimmunoglobulinasatherapeuticoptionfordeterioratingpatientswithcoronavirusdisease2019
AT linling highdoseintravenousimmunoglobulinasatherapeuticoptionfordeterioratingpatientswithcoronavirusdisease2019
AT ruanlianguo highdoseintravenousimmunoglobulinasatherapeuticoptionfordeterioratingpatientswithcoronavirusdisease2019
AT litaisheng highdoseintravenousimmunoglobulinasatherapeuticoptionfordeterioratingpatientswithcoronavirusdisease2019

Ejemplares similares